Cargando…

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

BACKGROUND: Rat sarcoma viral oncogene homolog (RAS) gene mutation is a common molecular event in colorectal cancer (CRC). The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Xuefeng, Zhong, Chenhan, Weng, Shanshan, Hu, Hanguang, Wang, Jian, Xiao, Qian, Wang, Jianwei, Sun, Lifeng, Xu, Dong, Liao, Xiujun, Dong, Caixia, Zhang, Suzhan, Li, Jun, Ding, Kefeng, Yuan, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354966/ https://www.ncbi.nlm.nih.gov/pubmed/37464378 http://dx.doi.org/10.1186/s12885-023-11139-z

Ejemplares similares

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
por: Fang, Xuefeng, et al.
Publicado: (2023)

Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX
por: Sasaki, Kenta, et al.
Publicado: (2019)

Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis
por: Hirata, Fumihiro, et al.
Publicado: (2018)

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016)

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
por: He, Jinjie, et al.
Publicado: (2023)

Efficacy of Aidi Injection and Brucea javanica Oil Emulsion Injection in Rectal Cancer during CapeOX Adjuvant Chemotherapy
por: Meng, Wenjun, et al.
Publicado: (2021)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
por: Iwamoto, Shigeyoshi, et al.
Publicado: (2018)

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
por: Nakayama, Goro, et al.
Publicado: (2017)

Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer
por: Fei, Zuo, et al.
Publicado: (2019)

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
por: Yamada, Y, et al.
Publicado: (2018)

CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial
por: Liu, Fangqi, et al.
Publicado: (2019)

An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect)
por: Matsuoka, Hiroshi, et al.
Publicado: (2020)

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
por: Liu, Yue, et al.
Publicado: (2022)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020
por: Dong, Caixia, et al.
Publicado: (2021)

Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report
por: Lin, Sen, et al.
Publicado: (2022)

Development and Characterization of Microsatellite Markers for the Cape Gooseberry Physalis peruviana
por: Simbaqueba, Jaime, et al.
Publicado: (2011)

Microsatellite genotypes of the South African Cape vulture, Gyps coprotheres
por: Kleinhans, Courtneë, et al.
Publicado: (2019)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Preoperative Nutritional Status Contributes to the Development of Neutropenia Event in Patients With Gastric Cancer Receiving CAPEOX Adjuvant Chemotherapy
por: Xiao, Ai Tang, et al.
Publicado: (2020)

Accuracy of Magnetic Resonance Imaging in Staging Rectal Cancer with Multidisciplinary Team: A Single-Center Experience
por: Yu, Linzhen, et al.
Publicado: (2019)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
por: Zeng, Xianghua, et al.
Publicado: (2023)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR‐mutated non‐small cell lung cancer patient: A case report
por: Zhang, Yiruo, et al.
Publicado: (2020)

Osteoblastic Bone Reaction Developing During Treatment With Sintilimab and Bevacizumab in a Patient With KRAS(G12V)-Mutant Lung Adenocarcinoma
por: Chen, Chang Jun, et al.
Publicado: (2023)

SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score–matched analysis
por: Huang, Xingmao, et al.
Publicado: (2023)

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
por: Hong, Guo, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
por: Lu, Nian, et al.
Publicado: (2023)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells
por: Wang, Zhanhuai, et al.
Publicado: (2017)

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
por: Zhang, Wen, et al.
Publicado: (2022)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

Microsatellite Instability and k‐ras, p53 Mutations in Thyroid Lymphoma
por: Takakuwa, Tetsuya, et al.
Publicado: (2000)

Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial
por: Li, Ruyuan, et al.
Publicado: (2022)

Sintilimab: Aggravation of Coronavirus disease 2019: case report
Publicado: (2021)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tn1fpmu8ofrp56grcptok2iemk